Understand the source comparison
Tesofensine vs Other Weight Loss Mechanisms: Clinical Trial Outcomes
Tesofensine 0.5mg Triple monoamine reuptake inhibitor (DAT/NET/SERT) 10.6% 14% Minimal rebound if tapered Semaglutide 2.4mg GLP-1 receptor agonist (gastric emptying delay) 14.9% 7% Two-thirds regained within 12 months Phentermine 37.5mg Norepinephrine releaser
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tesofensine 0.5mg
- Triple monoamine reuptake inhibitor (DAT/NET/SERT)
- 10.6%
- 14%
- Minimal rebound if tapered
- Semaglutide 2.4mg
- GLP-1 receptor agonist (gastric emptying delay)
- 14.9%
- 7%
- Two-thirds regained within 12 months
- Phentermine 37.5mg
- Norepinephrine releaser (sympathomimetic)
- 5.1%
- 22%
- Full rebound within 8 weeks
- Orlistat 120mg
- Lipase inhibitor (blocks fat absorption)
- 3.4%
- 31%
- No metabolic adaptation
- Lorcaserin 10mg (withdrawn)
- 5-HT2C agonist (selective serotonin pathway)
- 5.8%
- 18%
- Partial rebound
- Bottom Line
- Tesofensine delivers GLP-1-level outcomes through a purely central mechanism. No GI side effects, no injection requirement, but higher CNS-related adverse events (dry mouth, insomnia, increased heart rate). The triple-pathway design prevents the compensatory adaptation seen with single-target drugs.
- Tesofensine was never FDA-approved due to cardiovascular concerns during Phase III trials. Specifically, a dose-dependent increase in heart rate (4–7 bpm) and blood pressure (2–4 mmHg systolic). NeuroSearch halted development in 2010, but the compound remains available through research channels. Our tesofensine is synthesised under strict GMP conditions with third-party purity verification. We've maintained consistent batches for labs studying monoamine reuptake dynamics since 2018.